EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access

FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma

Sam Alhayo, Wing Kiu Chou, Lorenzo Giorgi, Nadia Guidozzi, Ewen A Griffiths, Sheraz R Markar, ALES Study Collaborative Group, Ella Seabourne, Riadh Salem, Stijn Vanstraelen, Helena Gielen, Johnny Moons und 44 weitere

JAMA Surgery · 01.09.2026 · 161 (9) · 917

DOI: 10.1001/jamasurg.2026.2703 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Surgery, erschienen am 01.09.2026. Verfasst von Sam Alhayo und 55 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper Gastrointestinal Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Pathological complete response (pCR) following neoadjuvant therapy is associated with favorable prognosis in esophageal adenocarcinoma. However, whether long-term outcomes differ by neoadjuvant modality among patients achieving pCR remains uncertain.

Objective

To compare survival outcomes and recurrence patterns in patients with esophageal or gastroesophageal junction adenocarcinoma achieving pCR after perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy vs the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study protocol (CROSS). Design, Setting, and Participants This cohort study was conducted at 14 high-volume European esophagogastric cancer centers between January 2018 and December 2024 with follow-up from surgery to death or last contact among patients with esophageal or junctional adenocarcinoma treated with neoadjuvant therapy followed by curative esophagectomy. Patients with squamous carcinoma, noncurative resection, incomplete pathological response, or 90-day mortality were excluded. Exposure Neoadjuvant perioperative FLOT chemotherapy or CROSS chemoradiotherapy followed by curative-intent esophagectomy. Main Outcomes and Measures The primary outcome was overall survival. Secondary outcomes included disease-free survival, recurrence patterns, and nodal stage–stratified survival. Survival was estimated using Kaplan-Meier methods and multivariable Cox proportional hazards models.

Results

Among 2717 eligible patients, 297 achieved pCR and were analyzed (mean [SD] age, 64.4 [9.7] years; 256 [79.5%] men). Of these, 150 received CROSS and 147 FLOT. FLOT patients were younger and more frequently clinically node-positive at baseline, while postoperative outcomes were similar. On unadjusted analysis, FLOT was associated with better overall survival (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60; P < .001) and disease-free survival (HR, 0.32; 95% CI, 0.19-0.55; P < .001). After adjustment, FLOT remained independently associated with better overall survival (HR, 0.34; 95% CI, 0.16-0.69; P = .003) and disease-free survival (HR, 0.35; 95% CI, 0.19-0.62; P < .001). Recurrence occurred in 13 of 147 patients receiving FLOT (8.8%) compared with 37 of 150 receiving CROSS (24.7%). Distant metastases predominated in the CROSS group (27 of 37 recurrences [70.3%]), whereas recurrence patterns were more heterogeneous after FLOT (locoregional, 2 of 13 recurrences [15.4%]; distant, 2 of 13 recurrences [38.5%]; both, 6 of 13 recurrences [30.8%]). The median (IQR) time to recurrence was longer after FLOT than CROSS (16.8 [12.3-21.5] vs 12.8 [7.1-26.7] months). In subgroup analyses, FLOT was associated with better survival in cN0 or 1 disease (HR, 0.32; 95% CI, 0.15-0.67; P = .002). Conclusions and Relevance In this cohort study, perioperative FLOT in patients achieving pCR for esophageal adenocarcinoma was associated with superior survival, lower recurrence risk, and later recurrence compared with CROSS. These findings suggest the prognostic significance of pCR may vary by neoadjuvant modality and should be interpreted in the context of treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansPathologic Complete ResponseNeoadjuvant TherapyMaleFemaleEsophagectomyMiddle AgedFluorouracilOxaliplatinDocetaxelLeucovorinAgedNeoplasm Recurrence, LocalSurvival RateEsophagogastric Junction

Substanzen

FluorouracilOxaliplatinDocetaxelLeucovorin

Autor:innen und Institutionen

  • Department of Upper Gastrointestinal Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Department of Upper GI and General Surgery, Footscray Hospital, Western Health, Victoria, Australia.
  • Grampians Health Ballarat, Grampians, Victoria, Australia.
  • Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Thoracic Surgery Department, University Hospital Leuven, Leuven, Belgium.

Zitieren

APA

Alhayo, S., Chou, W. K., Giorgi, L., Guidozzi, N., Griffiths, E. A., Markar, S. R., ALES Study Collaborative Group, Seabourne, E., Salem, R., Vanstraelen, S., Gielen, H., Moons, J., Nafteux, P., Lammes, F. E., Ruurda, J. P., van Hillegersberg, R., Todesco, A., D'Journo, X. B., Collizzolli, A., …, & van Berge Henegouwen, M. I. (2026). FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma. JAMA Surgery, 161(9), 917. https://doi.org/10.1001/jamasurg.2026.2703

Vancouver

Alhayo S, Chou WK, Giorgi L, Guidozzi N, Griffiths EA, Markar SR, et al. FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma. JAMA Surgery. 2026;161(9):917. doi:10.1001/jamasurg.2026.2703

BibTeX
@article{Alhayo2026,
  author = {Alhayo, Sam and Chou, Wing Kiu and Giorgi, Lorenzo and Guidozzi, Nadia and Griffiths, Ewen A and Markar, Sheraz R and ALES Study Collaborative Group, ALES Study Collaborative Group and Seabourne, Ella and Salem, Riadh and Vanstraelen, Stijn and Gielen, Helena and Moons, Johnny and Nafteux, Philippe and Lammes, Femke E and Ruurda, Jelle P and van Hillegersberg, Richard and Todesco, Alban and D'Journo, Xavier Benoit and Collizzolli, Alice and Ajazi, Barbara and Giacopuzzi, Simone and Bencivenga, Maria and Abu Hejleh, Aram and Schiffmann, Lars M and Bruns, Christiane J and Garbarino, Giovanni Maria and Pansa, Andrea and Basato, Silvia and Bacoeur-Ouzillou, Ophélie and Gronnier, Caroline and Henckens, Sofie P G and Gisbertz, Suzanne S and Ahmed, Rakesh and Loganathan, Nithiesh and Elliott, Jessie A and Cole, Kirsty and Ibrahim, Youssef and Anand, Chanakya and Pucher, Philip H and Skogar, Martin and Hedberg, Jakob and Bonnin, Eloise and Veziant, Julie and Piessen, Guillaume and Carresi, Agnese and Battaglia, Silvia and Rosati, Riccardo and Murad, Fahad and Klevebro, Fredrik and Nilsson, Magnus and Nieuwenhuijzen, Grard A P and van de Sanden, Lars and Luyer, Misha D P and Alfieri, Rita and Castoro, Carlo and van Berge Henegouwen, Mark I},
  title = {FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {9},
  pages = {917},
  doi = {10.1001/jamasurg.2026.2703}
}
Kostenlos starten →